CytomX Therapeutics Inc 2025年度报告

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the ExchangeAct. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financialreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of June 30, 2025, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock heldby non-affiliates of the registrant was approximately $372.3 million, based on the closing price of the registrant’s common stock on the Nasdaq Global Select Market on June30, 2025 of $2.27 per share. Shares of the registrant’s common stock held by each officer and director and each person known to the registrant to own 10% or more of theoutstanding common stock of the registrant have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determination forother purposes. As of February 28, 2026, 170,186,742 shares of the registrant’s common stock, $0.00001 par value per share, were outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement to be filed for its 2026 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxystatement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K. CYTOMX THERAPEUTICS, INC.ANNUAL REPORT ON FORM 10-KTABLE OF CONTENTS PART I ITEM 1.Business4ITEM 1A.Risk Factors32ITEM 1B.Unresolved Staff Comments74ITEM 1C.Cybersecurity74ITEM 2.Properties75ITEM 3.Legal Proceedings75ITEM 4.Mine Safety Disclosures75PART IIITEM 5.Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities76ITEM 6.[Reserved]76ITEM 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations77ITEM 7A.Quantitative and Qualitative Disclosures About Market Risk87ITEM 8.Financial Statements and Supplementary Data88ITEM 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure122ITEM 9A.Controls and Procedures122ITEM 9B.Other Information123ITEM 9C.Disclosure Regarding Foreign Jurisdictions That Prevent Inspections123PART IIIITEM 10.Directors, Executive Officers and Corporate Governance124ITEM 11.Executive Compensation124ITEM 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters124ITEM 13.Certain Relationships and Related Transactions, and Director Independence124ITEM 14.Principal Accountant Fees and Services124PART IVITEM 15.Exhibits and Financial Statement Schedules125ITEM 16.Form 10-K Summary128Signatures129 Forward-Looking Statements This Annual Report on Form 10-K contains certain forward-looking statements that involve risks and uncertainties. These forward-lookingstatements reflect our current views with respect to, among other things, future events and our financial performance. These statements areoften, but not always, made through the use of words or phrases such as “may,” “might,” “should,” “could,” “predict,” “potential,”“believe,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would,” “annualized” and“outlook,” or the negative version of those words or other compara